Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-DFO-REGN3767 PET in Relapsed/Refractory DLBCL
NCT04566978Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2020
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of 89Zr-DFO-REGN3767 in diffuse large B-cell lymphoma (DLBCL) (4 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Biodistribution of 89Zr-DFO-REGN3767 at 2 years, Optimal 89Zr-DFO-REGN3767 mass dose for tumor targeting at 2 years and 2 more. Started Sep 2020; status: completed.
02
Drugs
89Zr-DFO-REGN3767
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04566978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04566978.